Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Accumulated Expenses (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Accumulated Expenses for 4 consecutive years, with $54.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 20.42% to $54.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $54.6 million, a 20.42% decrease, with the full-year FY2025 number at $54.6 million, down 20.42% from a year prior.
  • Accumulated Expenses was $54.6 million for Q4 2025 at Day One Biopharmaceuticals, up from $48.2 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $68.6 million in Q4 2024 to a low of $7.3 million in Q1 2022.
  • A 4-year average of $31.4 million and a median of $26.5 million in 2023 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: soared 158.73% in 2024, then decreased 20.42% in 2025.
  • Day One Biopharmaceuticals' Accumulated Expenses stood at $16.0 million in 2022, then surged by 66.29% to $26.5 million in 2023, then skyrocketed by 158.73% to $68.6 million in 2024, then fell by 20.42% to $54.6 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Accumulated Expenses are $54.6 million (Q4 2025), $48.2 million (Q3 2025), and $43.6 million (Q1 2025).